Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Karuna Therapeutics, Inc. is conducting a Phase 3 global, multicenter study titled ‘A Phase 3 Global, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer’s Disease.’ The study aims to evaluate the long-term safety and tolerability of KarXT in individuals with Alzheimer’s-related psychosis, highlighting its significance in addressing this challenging condition.
The intervention being tested is KarXT, a drug composed of Xanomeline and Trospium Chloride, designed to manage psychosis symptoms in Alzheimer’s patients. This experimental treatment is administered in capsule form, with varying dosages to assess its effectiveness and safety over an extended period.
The study is interventional, employing a single-group model without masking, focusing primarily on treatment. Participants from previous related studies are eligible to enroll, ensuring a comprehensive evaluation of KarXT’s long-term effects.
The study began on July 11, 2023, with primary completion and estimated completion dates yet to be announced. The last update is scheduled for July 1, 2025, indicating ongoing progress and data collection.
This update could influence Karuna Therapeutics’ stock performance positively, as successful results may enhance investor confidence and market position. It also positions the company competitively within the Alzheimer’s treatment landscape, where innovative solutions are in high demand.
The study is currently recruiting, with further details available on the ClinicalTrials portal.